(Ivanhoe Newswire) -- Newer drugs used to treat benign prostatic
hyperplasia (BPH), otherwise known as an enlarged prostate, don’t appear to
raise the risk for a hip fracture.
That’s the key finding from researchers who compared outcomes from about 7,000
men who had suffered a hip fracture with those experienced by about 7,000 who
had not. Results showed men who had taken a 5-beta reductase inhibitor -- a
class of drugs that includes the medications finasteride and dutasteride -- were
no more likely to fracture their hip than men who had not taken these drugs.
The study did raise some concerns regarding an older class of medications for
BPH, however. The use of beta-blockers was slightly higher in men who had a hip
fracture than in men who didn’t, 32 percent versus 30 percent.
The researchers decided to study hip fracture incidence in men using these drugs
because the medications work by affecting hormones that play a role in bone
health.
“These data suggest that 5-beta reductase inhibitors do not confer a negative
risk for bone health and in fact may lower the risk of hip fracture,” write the
Kaiser Permanente Southern California researchers. “While presumably this lower
risk is related to hormonal mechanisms, further understanding of the biological
mechanisms underlying this phenomenon may lead to new insights that can be
exploited for preventive measures.”
SOURCE: Journal of the American Medical Association, published online October 7,
2008
